Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Publication year range
1.
Clin Genet ; 90(1): 21-7, 2016 Jul.
Article in English | MEDLINE | ID: mdl-26857110

ABSTRACT

We provide data on fetal growth pattern on the molecular subtypes of Beckwith-Wiedemann syndrome (BWS): IC1 gain of methylation (IC1-GoM), IC2 loss of methylation (IC2-LoM), 11p15.5 paternal uniparental disomy (UPD), and CDKN1C mutation. In this observational study, gestational ages and neonatal growth parameters of 247 BWS patients were compared by calculating gestational age-corrected standard deviation scores (SDS) and proportionality indexes to search for differences among IC1-GoM (n = 21), UPD (n = 87), IC2-LoM (n = 147), and CDKN1C mutation (n = 11) patients. In IC1-GoM subgroup, weight and length are higher than in other subgroups. Body proportionality indexes display the following pattern: highest in IC1-GoM patients, lowest in IC2-LoM/CDKN1C patients, intermediate in UPD ones. Prematurity was significantly more prevalent in the CDKN1C (64%) and IC2-LoM subgroups (37%). Fetal growth patterns are different in the four molecular subtypes of BWS and remarkably consistent with altered gene expression primed by the respective molecular mechanisms. IC1-GoM cases show extreme macrosomia and severe disproportion between weight and length excess. In IC2-LoM/CDKN1C patients, macrosomia is less common and associated with more proportionate weight/length ratios with excess of preterm birth. UPD patients show growth patterns closer to those of IC2-LoM, but manifest a body mass disproportion rather similar to that seen in IC1-GoM cases.


Subject(s)
Beckwith-Wiedemann Syndrome/genetics , Cyclin-Dependent Kinase Inhibitor p57/genetics , DNA Methylation , Fetal Development/genetics , Genomic Imprinting , Uniparental Disomy , Anthropometry , Beckwith-Wiedemann Syndrome/classification , Beckwith-Wiedemann Syndrome/diagnosis , Beckwith-Wiedemann Syndrome/pathology , Chromosomes, Human, Pair 11/chemistry , Fetus , Gene Expression , Genotype , Gestational Age , Humans , Infant, Newborn , Mutation , Phenotype , Premature Birth
2.
Endocr Dev ; 14: 53-60, 2009.
Article in English | MEDLINE | ID: mdl-19293574

ABSTRACT

Overgrowth syndromes are characterized by macrosomia, congenital anomalies, mental retardation and an increased risk of tumors. In this article we will analyze what we define 'classical' overgrowth.


Subject(s)
Beckwith-Wiedemann Syndrome/classification , Beckwith-Wiedemann Syndrome/physiopathology , Growth Disorders/classification , Growth Disorders/physiopathology , Beckwith-Wiedemann Syndrome/genetics , Growth Disorders/genetics , Humans , Syndrome
3.
Curr Opin Pediatr ; 17(6): 740-6, 2005 Dec.
Article in English | MEDLINE | ID: mdl-16282780

ABSTRACT

PURPOSE OF REVIEW: The clinical importance of overgrowth syndromes in the pediatric patient population has been increasingly recognized during the past decade, but clinical overlap among overgrowth syndromes often makes diagnostic categorization difficult. Advances in the molecular delineation of overgrowth syndromes in recent years have furthered our knowledge of the phenotypic spectrum of this group of conditions. This review focuses on developments in our understanding of the molecular mechanisms and phenotype-genotype correlations in the two most common overgrowth syndromes, Beckwith-Wiedemann syndrome and Sotos syndrome. The implications of these findings with respect to clinical diagnosis, medical management, and genetic counseling are discussed. RECENT FINDINGS: Recent reports have redefined the cardinal clinical features of Sotos syndrome, and the identification of two distinct types of molecular alterations in patients with this syndrome has enabled assessment of phenotype-genotype correlations. Recent studies in patients with Beckwith-Wiedemann syndrome have further expanded our understanding of the causative molecular mechanisms of this condition and provide evidence for specific genotype-phenotype correlations, most notably with respect to tumor risk. SUMMARY: Recognition of childhood overgrowth and investigation of diagnostic causes is important in anticipating appropriate medical management and facilitating the provision of genetic counseling. New developments in our understanding of the molecular basis and phenotypic expression of overgrowth syndromes provide additional tools in this often challenging process.


Subject(s)
Beckwith-Wiedemann Syndrome/genetics , Growth Disorders/genetics , Beckwith-Wiedemann Syndrome/classification , Beckwith-Wiedemann Syndrome/diagnosis , Child , Chromosomes, Human, Pair 11/genetics , Genomic Imprinting/genetics , Genotype , Growth Disorders/classification , Growth Disorders/diagnosis , Histone Methyltransferases , Histone-Lysine N-Methyltransferase , Humans , Intracellular Signaling Peptides and Proteins/genetics , Mutation/genetics , Nuclear Proteins/genetics , Phenotype , Syndrome , Translocation, Genetic , Uniparental Disomy/genetics
4.
Horm Res ; 54(1): 1-5, 2000.
Article in English | MEDLINE | ID: mdl-11182628

ABSTRACT

Beckwith-Wiedemann syndrome (BWS) is an overgrowth disorder involving developmental anomalies, tissue and organ hyperplasia and an increased risk of embryonic tumours (most commonly Wilms' tumour). This multigenic disorder is caused by dysregulation of the expression of imprinted genes in the 11p15 chromosomal region. It may involve paternal uniparental disomy (UPD), loss of imprinting of the IGF2 gene, maternal inherited translocations and trisomy with paternal duplication. Recently, a small proportion of BWS patients has been shown to have a mutation in the paternal imprinted p57(KIP2) gene, which encodes a cyclin-dependent kinase inhibitor and negatively regulates cell proliferation. We screened for p57(KIP2) gene mutations in 21 BWS patients with no 11p15 UPD in leucocyte DNA. All patients had a phenotype typical of BWS. We analysed the entire coding sequence of p57(KIP2), including intron-exon boundaries, by direct sequencing of five PCR-amplified fragments. No mutation was found in the p57(KIP2) gene. Our results are consistent with those of previous studies showing that mutation of p57(KIP2) is infrequent in BWS. Thus, other mechanisms of p57(KIP2) silencing (imprinting errors) and/or other 11p15 genes are probably involved in the pathogenesis of BWS.


Subject(s)
Beckwith-Wiedemann Syndrome/genetics , Chromosomes, Human, Pair 11 , Mutation , Nuclear Proteins/genetics , Polymorphism, Genetic , Beckwith-Wiedemann Syndrome/classification , Child , Child, Preschool , Chromosome Mapping , Cyclin-Dependent Kinase Inhibitor p57 , Enzyme Inhibitors , Exons , Female , Fetus , Genomic Imprinting , Humans , Infant , Introns , Male , Mutation, Missense , Sequence Deletion
6.
J Med Genet ; 34(5): 353-9, 1997 May.
Article in English | MEDLINE | ID: mdl-9152830

ABSTRACT

Beckwith-Wiedemann syndrome (BWS) is a congenital overgrowth syndrome associated with a characteristic pattern of visceromegaly and predisposition to childhood tumours. BWS is a genetically heterogeneous disorder; most cases are sporadic but approximately 15% are familial and a small number of BWS patients have cytogenetic abnormalities involving chromosome 11p15. Genomic imprinting effects have been implicated in familial and non-familial BWS. We have investigated the molecular pathology of 106 sporadic BWS cases; 17% (14/83) of informative cases had uniparental disomy (UPD) for chromosome 11p15.5. In each case UPD appeared to result from a postzygotic event resulting in mosaicism for segmental paternal isodisomy. The critical region for isodisomy was refined to a 25 cM interval between D11S861 and D11S2071 which contained the IGF2, H19, and p57(KIP2) genes. In three cases isodisomy for 11q markers was detected but this did not extend further than 11q13-q21 suggesting that complete chromosome 11 disomy may not produce a BWS phenotype. The allele specific methylation status of the H19 gene was investigated in 80 sporadic BWS cases. All 13 cases with UPD tested displayed hypermethylation consistent with an excess of paternal H19 alleles. In addition, five of 63 (8%) cases with normal biparental inheritance had H19 hypermethylation consistent with an "imprinting centre" mutation (ICM) or "imprinting error" (IE) lesion. The phenotype of patients with putative ICM/IE mutations was variable and overlapped with that of non-UPD sporadic BWS cases with normal H19 methylation. However, exomphalos was significantly (p < 0.05) more common in the latter group. These findings may indicate differential effects on the expression of imprinted genes in chromosome 11p15 according to the precise molecular pathology. Analysis of H19 methylation is useful for the diagnosis of both UPD or altered imprinting in BWS and shows that a variety of molecular mechanisms may cause relaxation of IGF2 imprinting in BWS.


Subject(s)
Beckwith-Wiedemann Syndrome/genetics , Genomic Imprinting/genetics , Muscle Proteins/metabolism , RNA, Untranslated , Aneuploidy , Beckwith-Wiedemann Syndrome/classification , Beckwith-Wiedemann Syndrome/diagnosis , Chromosomes, Human, Pair 11 , DNA Methylation , Female , Humans , Male , Muscle Proteins/genetics , Phenotype , RNA, Long Noncoding
8.
Akush Ginekol (Mosk) ; (6): 23-6, 1990 Jun.
Article in Russian | MEDLINE | ID: mdl-2221257

ABSTRACT

The paper presents a classification of tall stature and clinical and hormonal findings in 35 girls in the age range of 11 to 18 years with constitutional tall stature. They showed a normal decline in growth hormone (GH) concentrations in the second phase of pubertal maturation. Concentrations of GH clearly correlated with the menstrual status. They were low in regularly menstruating girls, higher in non-menstruating girls and highest in tall girls with irregular menstrual cycles. Estrogen therapy in 7 girls decelerated growth rates and promoted epiphyseal ossification. Regular menstrual cycles established after withdrawal of therapy in all patients.


Subject(s)
Beckwith-Wiedemann Syndrome/etiology , Body Height/physiology , Estradiol Congeners/therapeutic use , Gigantism/etiology , Growth , Somatomedins/metabolism , Adolescent , Beckwith-Wiedemann Syndrome/classification , Beckwith-Wiedemann Syndrome/drug therapy , Child , Female , Gigantism/classification , Gigantism/drug therapy , Growth Inhibitors , Humans , Puberty/physiology , Somatomedins/antagonists & inhibitors
SELECTION OF CITATIONS
SEARCH DETAIL
...